

gastric carcinoma. One of its major virulence determinants is cytotoxin associated gene A, *cagA*, and high levels of *cagA* expression are associated with more severe disease. The functional promoter elements of *cagA* in the 436 bp *cagAB* intergenic region have been previously analysed but differences in the promoter region and levels of *cagA* expression between different *H pylori* strains have not been studied in detail. We aimed to analyse the *cagA* promoter region to determine whether naturally occurring polymorphic differences within it contribute to differences in *cagA* expression level.

**Methods** Biopsy samples were obtained from 17 patients undergoing routine upper GI endoscopy at the Queen's Medical Centre Nottingham, UK. RNA was extracted directly from biopsies and *cagA* expression levels were analysed by real-time qPCR. The *cagAB* intergenic region of all 17 clinical strains were sequenced and aligned using the ClustalW multiple sequence alignment program and ranked in order of *cagA* transcript levels. A potentially relevant natural mutation was then created artificially by site-directed mutagenesis to prove its importance.

**Results** A potentially important polymorphism was identified within an imperfect inverted repeat where an A was commonly replaced by a T at position -54. Strains possessing T at this position expressed higher *cagA* mRNA levels than those with an A ( $p=0.016$ ). To test whether this was a direct determinant of *cagA* transcription level, a mutation was engineered at position -54 (T to A) in high transcription strain 83. This resulted in a 30% reduction in *cagA* transcript level when compared to an isogenic control strain without the change ( $p=0.073$ ). In the complementary experiment, we engineered an A to T mutation in low transcription strain 126 and this led to a 20% increase in the level of *cagA* mRNA compared to its isogenic control ( $p=0.002$ ).

**Conclusion** Presence of a T at position -54 within the inverted repeat of the *cagA* promoter region is an important natural determinant of higher levels of *cagA* transcription. We speculate that this may help explain why only some *cagA*<sup>+</sup> *H pylori* strains cause disease.

**Competing interests** None declared.

## PWE-160 LIVER RESECTION IN METASTATIC GASTROINTESTINAL STROMAL TUMOURS

doi:10.1136/gutjnl-2012-302514d.160

S S Mudan, A B Fajardo-Puerta.\* *Department of General surgery, The Royal Marsden, London, UK*

**Introduction** The benefit, if any and case selection for operation in metastatic GIST has not as yet been evaluated. We report our experience with patients undergoing liver resection for metastatic GIST.

**Methods** From a prospectively held data base spanning 2000–2011 we identified 12 patients who underwent liver resection and cases notes reviewed. Non-parametric statistics were applied.

**Results** The M:F ratio was 5:7. The median age at diagnosis of the primary tumour was 55 yr, range 47–71 yr. The site of primary was: Gastric 6, duodenum 1, small intestine 2, colon 2, rectum 1. In three cases liver metastases were present at diagnosis of the primary and these patients underwent synchronous resection of the primary and liver. In the remainder the median disease free interval was 12 m (2–96 m). In nine cases the pattern of metastatic disease was hepatic alone, two cases had in addition peritoneal disease and both had had percutaneous biopsy of the primary tumour. One case had local recurrence. All but one patient received neoadjuvant chemotherapy with imatinib and in two cases 2nd-line treatment with sunitinib and 1 3rd-line with nilotinib. The median duration of systemic therapy before operation was 18 m (10–84) and systemic therapy was stopped after plateau of response or evidence of

progression, non-responders were not considered for resection. Liver resections performed: Right extended 1, right 3, left 1, non-anatomic or segmental 7. Additional visceral resection required in 2 (synchronous primary cases excepted). At a median follow-up time of 43 m from liver resection the status is: NED 7, AWD 3, DOC 1, DOD 1. There was no 30-day mortality.

**Conclusion** The safety of hepatectomy for GIST in the imatinib treated patient is demonstrated. Whether resection of metastatic disease translates into cure, at least in some patients is yet to be proven but it is suggested that the indications for liver resection for metastatic disease might be extended to this disease.

**Competing interests** None declared.

## PWE-161 PLATELET ACTIVATION IN ACUTE UPPER GASTROINTESTINAL BLEEDING

doi:10.1136/gutjnl-2012-302514d.161

<sup>1</sup>B R Disney, \*<sup>2</sup>R Watson, <sup>2</sup>A Blann, <sup>2</sup>G Lip, <sup>3</sup>C Tselepis, <sup>1</sup>M Anderson. <sup>1</sup>*Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK*, <sup>2</sup>*Department of Cardiology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK*; <sup>3</sup>*Department of Cancer Sciences, University of Birmingham, Birmingham, UK*

**Introduction** Acute upper gastrointestinal bleeding (AUGIB) is a common reason for medical admissions and is associated with significant morbidity and mortality. Studies have previously noted an excess of cardiovascular events in patients who have suffered from AUGIB. Patients who have aspirin withheld for 8 weeks following admission with AUGIB have significantly higher rates of CVS events. The aim of the study was to assess the level of platelet activation, and platelet reactivity, in patients presenting with AUGIB.

**Methods** Patients admitted to Sandwell and West Birmingham Hospitals NHS Trust with AUGIB were recruited. Dyspeptic patients attending for diagnostic OGD were used as controls. To assess platelet activation citrated whole blood was incubated at room temperature with monoclonal mouse antibodies against constitutively expressed platelet marker CD42a-PerCP, and markers of platelet activation PAC1-FITC, and CD62P-APC. Negative controls were run in parallel. Incubation was terminated after 15 min. Platelet reactivity to an agonist, in this case ADP, was assessed by stimulating blood with ADP for 2 min prior to incubation with antibodies as described above. Samples were analysed using a FACSCalibur flow cytometer. Platelets were identified on the basis of their forward and side scatter properties and the presence of the CD42a platelet-specific marker. CD62P and PAC1 expression were measured by the percentage of platelets expressing these markers. Statistical significance of mean platelet activation was determined by the t-test. The Mann–Whitney U test was utilised for non-normally distributed data. Statistical analysis was performed using SPSS V.18.0 software.

**Results** A total of 31 patients with AUGIB and 25 controls were recruited. The groups were age and gender matched. The mean age of the AUGIB group is 66.4±18.2 years, and the control group 62.8±6.1 years. There was a significant differences in the level of CD62P positivity between the study groups (18.4±5.8% in AUGIB group and 13.9±3.7% in the control group,  $p=0.001$ ) and in those staining positive for both CD62P and PAC1 (1.9±1.45% in AUGIB group and 1.2±1.0% in the control group,  $p=0.027$ ). No differences were seen in PAC1 positivity between the groups (7.1±5.2 vs 5.1±4.2,  $p=0.127$ ). No differences were seen in the response of platelets to ADP between the study and control groups.

**Conclusion** Patients presenting with AUGIB have higher levels of platelet activation when compared to controls. Platelet reactivity to

ADP was similar between the two groups. In patients with high cardiovascular risk profiles early re-introduction of aspirin or other anti-platelet agents should be considered.

**Competing interests** None declared.

### PWE-162 SEASONAL AND DIURNAL VARIATION IN THE PRESENTATION AND SEVERITY OF ACUTE UPPER GASTROINTESTINAL BLEEDING

doi:10.1136/gutjnl-2012-302514d.162

<sup>1</sup>B R Disney, \*<sup>2</sup>R Watson, <sup>2</sup>A Blann, <sup>2</sup>G Lip, <sup>3</sup>C Tselepis, <sup>1</sup>M Anderson. <sup>1</sup>Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; <sup>2</sup>Department of Cardiology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; <sup>3</sup>Department of Cancer Sciences, University of Birmingham, Birmingham, UK

**Introduction** Acute upper gastrointestinal bleeding is a medical emergency associated with a significant health burden and risk of mortality. Previous studies have looked for diurnal and seasonal variations in presentation. No studies have addressed these issues in the UK population.

**Methods** All patients admitted with acute upper gastrointestinal bleeding to Sandwell and West Birmingham Hospitals NHS Trust from 1 January 2009 to 31 December 2009 were included in the study. Diurnal and seasonal differences in presentation were analysed using the  $\chi^2$  test; differences in Rockall and Blatchford scores were analysed using the Kruskal–Wallis test followed by the Mann–Whitney U test, with Bonferroni correction, to assess differences between individual groups.

**Results** Overall, 470 patients with acute upper gastrointestinal bleeding were admitted during the study period. Of these 67.2% were male and 32.8% female. The mean age of patients was  $64.0 \pm 18.8$  years. Significant differences were seen in both diurnal and seasonal variation. Patients were more likely to present between the hours of 12:01–18:00 ( $p < 0.001$ ). Admission rates were lower during the winter months ( $p = 0.028$ ). The Rockall score showed significant diurnal variation ( $p = 0.048$ ). No diurnal variation was seen in the Blatchford score ( $p = 0.39$ ).

**Conclusion** Acute upper gastrointestinal bleeding shows a significant diurnal and seasonal variation in presentation. Diurnal variation is observed in Rockall scores, although this is of doubtful clinical relevance. The variation in presentation of acute upper gastrointestinal bleeding may have implications for the provision of endoscopy services.

**Competing interests** None declared.

### PWE-163 FACTORS PREDICTING EXTENDED LENGTH OF STAY FOLLOWING LAPAROSCOPIC NISSEN FUNDOPLICATION: A MOVE TOWARDS DAY CASE SURGERY

doi:10.1136/gutjnl-2012-302514d.163

B Alkhaffaf, \* P Turner, R Date, M Mughal, J Ward, K Pursnani. Department of Oesophago-Gastric Surgery, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK

**Introduction** There has been a move towards performing laparoscopic gastric fundoplication as a “day-case” procedure. This study aimed to determine which factors influence length of stay (LOS) to better enable patient selection for “day-case” fundoplication.

**Methods** This was a retrospective study of 229 consecutive laparoscopic Nissen fundoplications performed between 1999 and 2011. The primary outcome measure was length of hospital stay (LOS). Factors examined were patient age, main indication for surgery

(large hiatus hernia or gastro-oesophageal reflux disease (GORD) and primary or redo surgery), history of previous surgery and presence and size of hiatus hernia.

**Results** Patients undergoing surgery for large hiatus herniae had an average 2-day greater LOS compared to those undergoing surgery for GORD ( $p < 0.001$ ). Surgery for large hiatus herniae was also associated with a higher rate of conversion to open surgery (41% vs 7%;  $p < 0.001$ ). LOS was not affected by small or moderate sized hiatus herniae. A history of previous open upper abdominal surgery increased LOS by an average of 2 days ( $p = 0.010$ ) and was associated with a higher rate of conversion to open surgery when compared to cases with no past surgical history (40% vs 12.7%;  $p = 0.036$ ). Redo fundoplication surgery led to an increased LOS by an average of 1.5 days ( $p = 0.044$ ) when compared to primary surgery. There was a positive correlation between age and LOS ( $p = 0.007$ ).

**Conclusion** Factors which should exclude patients from undergoing “day-case” fundoplication include; large hiatus hernia as the main indication for intervention, redo surgery, a history of previous open upper abdominal surgery and advancing age.

**Competing interests** None declared.

### PWE-164 ASSESSMENT OF HELICOBACTER PYLORI IN IRON DEFICIENCY ANAEMIA: DO WE DO THIS?

doi:10.1136/gutjnl-2012-302514d.164

C Daker, \* M Haji-Coll, N van Someren, K Besherdas. Department of Gastroenterology, Chase Farm Hospital, London, UK

**Introduction** Globally iron deficiency anaemia (IDA) is responsible for over two billion cases. In the western world, an estimated 2–5% of adult men and post menopausal woman suffer with IDA. GI losses account for many cases and patients will undergo endoscopy to exclude pathology here. Recent evidence suggests that infection with *H pylori* (HP) should be considered despite the absence of peptic ulcer disease or other bleeding lesions in the GI tract. Hypothesised mechanisms for HP causing IDA are: chronic gastritis causing active bleeding, so iron is lost, achlorhydria decreasing iron absorption, the possibility that HP itself directly acquires iron so competing with the host, and also the possibility of an anaemia of chronic disease.

**Methods** The study aim was to determine whether patients with IDA referred for an gastroscopy (OGD) had a rapid urease test (CLO test) performed to confirm infection with HP. This was a single centre, retrospective analysis of consecutive patients endoscoped for IDA over 1 year upto January 2011. The endoscopy report was scrutinised for the performance of the CLO test and if performed the result was noted.

**Results** 194 Of 473 (41%) patients undergoing OGD for IDA had their CLO test obtained. Of these 27 of 194 (5.7%) were positive with 167 of 194 negative CLO tests.

**Conclusion** In this study, 59% of patients endoscoped for IDA did not have a HP test. We may be missing a simple treatable cause for IDA in the upper GI tract within this group of patients. Of those who were not tested (270) 71 exhibited other significant pathology (angiodysplasia, gastric/colonic cancer, peptic ulcers). The association of IDA with HP is not universally recognised and we believe may be the reason as seen in this study not tested for in the absence of peptic ulcer disease or another cause for bleeding when endoscoping patients for IDA. We recommend routine testing (and eradication if detected) of HP in patients IDA undergoing OGD. In addition, testing and eradicating for HP may also reduce the risk of development of gastritis, peptic ulcer, MALToma and gastric cancer in those found to have the bacteria.